Supercharge Your Innovation With Domain-Expert AI Agents!

HIG2 and URLC10 epitope peptide and vaccines containing the same

一种氨基酸、抗原的技术，应用在治疗和预防肿瘤的药物领域，能够解决低客观应答率等问题

Active Publication Date: 2015-10-07
ONCOTHERAPY SCI INC
View PDF23 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, only low objective response rates have been observed so far in these cancer vaccine trials (NPL 11: Belli F et al., J Clin Oncol 2002 Oct 15,20(20):4169-80; NPL 12: Coulie PG et al., Immunol Rev 2002Oct, 188:33-42; NPL 13: Rosenberg SA et al., Nat Med 2004Sep, 10(9):909-15)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HIG2 and URLC10 epitope peptide and vaccines containing the same
  • HIG2 and URLC10 epitope peptide and vaccines containing the same
  • HIG2 and URLC10 epitope peptide and vaccines containing the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0221] Materials and methods

[0222] cell line

[0223] PSCCA0922 (HLA-A0206) was purchased from Pharma SNP Consortium; PSC. Human B-lymphoblastoid cell line and COS7 were purchased from ATCC.

[0224] Candidate peptides derived from HIG2 or URLC10

[0225] 9-mer and 10-mer peptides derived from HIG2 or URLC10 were synthesized by Sigma (Sapporo, Japan) or Biosynthesis Inc. (Lewisville, TX) following standard solid-phase synthesis and analyzed by reverse-phase high-performance liquid chromatography (HPLC). Purification was performed. The purity (>90%) and identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Peptides were dissolved in dimethyl sulfoxide (DMSO) at 20 mg / ml and stored at -80°C.

[0226] In vitro CTL induction

[0227]Monocyte-derived dendritic cells (DCs) were used as antigen presenting cells (APCs) to induce cytotoxic T lymphocyte (CTL) responses against peptides presented on human leukocyte antige...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and / or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.

Description

[0001] This application is a divisional application of a Chinese invention patent application with an application date of August 14, 2009, an application number of 200980141320.6, and an invention title of "HIG2 and URLC epitope peptides and vaccines containing them". technical field [0002] priority [0003] This application claims the benefit of US Provisional Application No. 61 / 089,972, filed August 19, 2008, the entire contents of which are hereby incorporated by reference. technical field [0004] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. Specifically, the present invention relates to novel peptides that are extremely effective as cancer vaccines, and drugs for treating and preventing tumors. Background of the invention [0005] It has been demonstrated that CD8-positive CTLs can recognize tumor-associated antigen (TAA)-derived epitope peptides appearing on major histocompatibility compl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61K39/00C12N5/0786C12N5/0784C12N5/0783C07K14/47A61P35/00
CPCA61K39/0011A61K38/00C07K14/7051A61P35/00A61P37/04A61K38/08A61K38/1774A61K2039/572A61K2039/5154
Inventor 角田卓也大泽龙司吉村祥子
Owner ONCOTHERAPY SCI INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com